Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Contrarian Investing -- Ignore unavailable to you. Want to Upgrade?

To: pcyhuang who wrote (43)	9/18/2006 11:12:17 AM
From: Biomaven	Read Replies (1) \| Respond to of 4080

Biovail Corp (BVF @$14.70) Forward P/E (fye 31-Dec-07): 8.47; PEG Ratio (5 yr expected): 0.78; Price/Sales (ttm): 2.56; Price/Book (mrq): 1.93; 52-Week High (23-Mar-06)3: 28.28; 52-Week Low (02-Aug-06)3: 15.51; Qtrly Revenue Growth (yoy): 16.90% Qtrly Earnings Growth (yoy): 2074.10%. But you have to look at the fundamental picture as well - 40% of its current revenue is imminently at-risk to a generic launch of Wellbutrin XL. Peter